J. Goldman & Co’s Viking Therapeutics VKTX Stock Holding History

J. Goldman & Co’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$589K	Sell	15,089 -205	-1%	-$6.62K	0.02%	530
2026 Q1	$498K	Sell	15,294 -18,364	-55%	-$590K	0.01%	505
2025 Q4	$1.18M	Buy	+33,658	New	+$1.19M	0.03%	365
2025 Q1	–	Sell	-14,456	Closed	-$457K	–	654
2024 Q4	$582K	Buy	+14,456	New	+$824K	0.02%	358
2023 Q4	–	Sell	-92,219	Closed	-$1.02M	–	485
2023 Q3	$1.02M	Buy	+92,219	New	+$1.32M	0.04%	237
2022 Q4	–	Sell	-135,000	Closed	-$603K	–	503
2022 Q3	$367K	Buy	+135,000	New	+$442K	0.02%	311
2019 Q4	–	Sell	-12,857	Closed	-$88K	–	357
2019 Q3	$88K	Buy	+12,857	New	+$95.5K	0.01%	266
2018 Q3	–	Sell	-82,698	Closed	-$785K	–	396
2018 Q2	$785K	Buy	+82,698	New	+$550K	0.04%	268

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

J. Goldman & Co's VKTX Position: Q2 2026 in Review

J. Goldman & Co reduced its Viking Therapeutics (VKTX) stake by 1.3% in Q2 2026, selling an estimated $6.62K and leaving 15,089 shares worth $589K. The position accounts for 0.02% of the portfolio, ranked #530.

J. Goldman & Co first reported a position in VKTX in Q2 2018 and has held it in 8 quarters since. The position peaked at $1.18M in Q4 2025. 434 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

J. Goldman & Co held 15,089 shares of Viking Therapeutics worth $589K as of Q2 2026.
J. Goldman & Co sold 205 Viking Therapeutics shares in Q2 2026, an estimated $6.62K.
Viking Therapeutics made up 0.02% of J. Goldman & Co's portfolio in Q2 2026, its #530 holding.
J. Goldman & Co first reported a position in Viking Therapeutics in Q2 2018 and has held it in 8 quarters since.
J. Goldman & Co's Viking Therapeutics position peaked at $1.18M in Q4 2025.
434 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.